Navigation Links
Two Drugs Better Than One for Crohn's Patients
Date:6/3/2009

Remission rates higher with combination therapy, study finds

WEDNESDAY, June 3 (HealthDay News) -- Crohn's disease patients who received a combination of the drugs infliximab (Remicade) and azathioprine (Azasan) were more likely to have the disease go into steroid-free remission than those who received only one of the drugs, researchers say.

The study was presented Tuesday at Digestive Disease Week 2009 in Chicago.

Crohn's disease is an inflammation of the digestive tract, most often the lining and wall of the lower small intestine, or the ileum, according to the National Digestive Diseases Information Clearinghouse. When inflamed, the lining of the intestinal wall can become swollen, causing diarrhea. Severe cases can require surgery.

In an international study, researchers divided 508 patients with moderate to severe Crohn's who had not yet received immunomodulator drugs into three groups. One group received infliximab plus azathioprine, a second group received infliximab plus a placebo and the third group received azathioprine plus a placebo for 30 weeks, with the option to continue in a blinded study extension through week 50.

After 50 weeks, 72.2 percent of patients who'd received the infliximab/azathioprine drug combination were in steroid-free remission, compared to 60.8 percent who'd received infliximab alone and 54.7 percent who had taken azathioprine alone, according to a Digestive Disease Week news release.

The researchers used colonoscopies and a Crohn's Disease Activity Index score to measure clinical symptoms. Assuming the patients who did not enroll in the study extension continued to have Crohn's symptoms at week 50, the proportion of the patients who were in steroid-free remission at week 50 was 46.2 percent with infliximab plus azathioprine, 34.9 percent with infliximab monotherapy and 24.1 percent with azathioprine monotherapy, the study found.

Looking at all treatment groups, the percentage of patients who developed serious infections was similar in all groups, and during the study extension there were no new opportunistic infections, malignancies or deaths.

"Results of this study will provide practitioners and their patients with more clinical data on how to use these drugs most appropriately to most effectively treat Crohn's disease," study author Dr. William J. Sandborn, vice chair of the division of gastroenterology and hepatology at the Mayo Clinic in Rochester, said in the news release. "For the first time, we have longer-term outcome data on the advantages of combination therapy that will help guide our treatment of patients with Crohn's disease."

Monoclonal antibodies, such as infliximab, are increasingly used to treat several types of gastroenterological disorders.

"The use of monoclonal antibodies is rising for a number of gastroenterological disorders, such as inflammatory bowel disease," said Dr. Nicholas J. Shaheen, of the University of North Carolina School of Medicine, in the news release. "New indications for these treatments are continuing to be developed and the safety profile is better understood, making them good treatment options for patients with recurrent or chronic gastrointestinal diseases."

This study is the first to provide longer term data on the benefits of combination infliximab-azathioprine and infliximab therapy. In the study, patients were started on the drugs earlier in the course of the disease than typically occurs, Sanborn noted.

More information

For more on Crohn's disease, visit the National Digestive Diseases Information Clearinghouse.



-- Jennifer Thomas



SOURCE: Digestive Disease Week, news release, June 2, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. China Nepstar Chain Drugstore Appoints Chief Operating Officer
2. Mylans Chief Operating Officer Heather Bresch to Testify Before Congress Concerning Patent Settlements Between Brand and Generic Pharmaceutical Companies and Tactics That Delay Market Entry of High Quality, Affordable Generic Drugs
3. drugstore.com, inc. to Present at Upcoming Financial Conferences
4. Isis Highlights New Clinical Data on Anti-Cancer Antisense Drugs Featured at ASCO
5. Two Drugs Safe for Rare Forms of Kidney Cancer
6. Marijuana rivals mainstream drugs for HIV/AIDS symptoms
7. Dementia drugs may put some patients at risk, Queens study shows
8. In the Case of Epilepsy, Generic Drugs and Random Product Substitution are Not Always "Good Medicine"
9. China Nepstar Chain Drugstore Reports First Quarter 2009 Financial Results
10. China Nepstar Chain Drugstore Filed 2008 Annual Report on Form 20-F
11. Launch of Highly Anticipated Oral Agents and Increasing Use of Current and Emerging Injectable Drugs Will Drive the Multiple Sclerosis Drug Market to Nearly $10 Billion in 2018
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Two Drugs Better Than One for Crohn's Patients
(Date:5/6/2016)... ... May 06, 2016 , ... Logically, spring weather, with its moderate ... weather is too cold, dry or hot, water on the eye surface can evaporate, ... from the surrounding air. There’s only one problem, according to radio show and water ...
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... From May ... Chicago, IL, offering EarQ members the unique opportunity to learn more about Signia’s technology ... independent practice growth. , “It is our priority to see practices succeed in this ...
(Date:5/6/2016)... , ... May 06, 2016 , ... Canadian author Mark Black is a ... Life From the Heart" around the world … with the help of his publisher Strategic ... 24, Mark Black lay in a hospital bed waiting for a miracle: He needed a ...
(Date:5/6/2016)... , ... May 06, 2016 , ... ... to Sleepopolis.com . , Since launching in September, 2014 Sleepopolis has resided ... testing areas, which now include pillows, sheets, mattress toppers, bed frames, and more. ...
(Date:5/6/2016)... Abilene, Texas (PRWEB) , ... May 06, 2016 , ... Yisrayl Hawkins, Pastor and Overseer ... scientists and doctors, worldwide, what he has found in the Bible about helping to stop ... address it, and it is his hope that the health and science industries will pay ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... 2016 Research and Markets has announced the ... 5 EU Markets"  report to their offering.  ,     (Logo: ... on the current Positron Emission Tomography (PET) scanner and cyclotron ... which includes France , Germany ... and the United Kingdom . ...
(Date:5/5/2016)... 5, 2016 Research ... "Europe Systemic Lupus Erythematosus Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Europe Systemic Lupus Erythematosus Market and Competitive ... into Systemic Lupus Erythematosus pipeline products, Systemic ...
(Date:5/4/2016)... , May 4, 2016 BiondVax ... CEO, Dr. Ron Babecoff , will be attending the ... City . On Thursday, May 5, Dr. ... conference presented by Joseph Gunner & Co, taking ... BiondVax presentation that Dr. Babecoff will be using is downloadable ...
Breaking Medicine Technology: